With pharma and medtech Q1 earnings season now at a close, some sector areas performed better than others.

In this episode, Robert Barrie, editor for Pharmaceutical Technology, and Ross Law, reporter at Medical Device Network, discuss the key trends from the quarter. In pharma, weight loss therapies and patent expirations dominated bottom lines.

Eli Lilly's Mounjaro (tirzepatide) became the top-selling drug in the quarter, ousting MSD's Keytruda (pembrolizumab) in a changing of the guard. Meanwhile, the looming patent cliff is placing emphasis on late-stage pipelines and dealmaking activity for many companies.

In medtech, geopolitical pressures meant some companies chose to revise their 2026 outlook. Trade through the Strait of Hormuz, one of the world’s most critical maritime chokepoints, has ongoing disruption, meaning the shipping of goods is currently more expensive.

You can listen to the episode here:

Eli Lilly, Novartis, GE HealthCare, and Stryker, amongst others, are covered.